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Abstract
Background: The Down syndrome phenotype has been attributed to overexpression of
chromosome 21 (Hsa21) genes. However, the expression profile of Hsa21 genes in trisomic human
subjects as well as their effects on genes located on different chromosomes are largely unknown.
Using oligonucleotide microarrays we compared the gene expression profiles of hearts of human
fetuses with and without Hsa21 trisomy.
Results: Approximately half of the 15,000 genes examined (87 of the 168 genes on Hsa21) were
expressed in the heart at 18–22 weeks of gestation. Hsa21 gene expression was globally
upregulated 1.5 fold in trisomic samples. However, not all genes were equally dysregulated and 25
genes were not upregulated at all. Genes located on other chromosomes were also significantly
dysregulated. Functional class scoring and gene set enrichment analyses of 473 genes, differentially
expressed between trisomic and non-trisomic hearts, revealed downregulation of genes encoding
mitochondrial enzymes and upregulation of genes encoding extracellular matrix proteins. There
were no significant differences between trisomic fetuses with and without heart defects.
Conclusion: We conclude that dosage-dependent upregulation of Hsa21 genes causes
dysregulation of the genes responsible for mitochondrial function and for the extracellular matrix
organization in the fetal heart of trisomic subjects. These alterations might be harbingers of the
heart defects associated with Hsa21 trisomy, which could be based on elusive mechanisms involving
genetic variability, environmental factors and/or stochastic events.
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Down syndrome (DS) is the most frequent autosomal
aneuploidy that is compatible with post-natal life. It
results from complete or partial trisomy of chromosome
21 (Hsa21) and is characterized by a complex phenotype
in which over 80 features occur with various degrees of
expression and frequency [1]. Down syndrome is a major
cause of congenital heart defects (CHD). It is associated
mostly with endocardial cushion defects [2,3], the most
frequent being atrioventricular canal defects (AVCD) fol-
lowed by ventricular septal defects (VSD) and tetralogy of
Fallot [3].
Attempts to identify the Hsa21 genes that contribute to
the DS phenotype have focused on the Down Syndrome
Critical Region (DSCR) which spans approximately 5.4
Mb in band 21q22.3 [4-7]. The DSCR hypothesis predicts
that a gene, or genes, in this region are sufficient to pro-
duce the specific DS features when present in three copies.
A narrowed region was also proposed as the candidate
region for DS-CHD [8]. The DSCR hypothesis was tested
in mice [9,10] and it was found that trisomy for DSCR
alone is necessary but not sufficient for brain phenotypes
in trisomic mice. These results suggest that the origins of
trisomic phenotypes are even more complicated than for-
merly assumed and that they probably involve multiple
gene interactions [10]. It has been proposed that the com-
plex phenotypic alterations of DS could result from an
interplay between Hsa21 genes and developmentally reg-
ulated genes elsewhere on the genome [11] and that the
loss of genetic balance in pivotal processes regulating
development might increase susceptibility to genetic and
environmental insults [12].
The mechanism by which an extra copy of chromosome
21 produces the DS phenotype is unknown and is possi-
bly complex. It has been postulated that a triplicated chro-
mosome 21 causes a 50% increase in the expression of
trisomic genes as a primary dosage effect [13]. With the
advent of microarrays and other high-throughput tech-
nologies, it became possible to demonstrate this primary
dosage effect. By measuring the steady-state-RNA levels in
human DS tissues and cells [14-17] and in tissues from
mouse models of DS [18-22] it has been established that
the trisomy causes an overall 50% increase in the RNA lev-
els of Hsa21 genes. At least some of this RNA increase
might result in perturbations of the pathways and cellular
processes in which these genes function [23]. This can
affect cardiac development and result in CHD [16].
Given the number of candidate genes involved, the
number of alternative splice variants of individual genes
and the number of pathways in which these genes func-
tion, pathway analysis seems the most suitable approach
to the study of genotype/phenotype correlations in DS
[23]. Data from functional studies suggest that multiple
chromosome 21 genes affect protein processing, mito-
chondrial function and reactive oxygen species produc-
tion, one-carbon metabolism and cell adhesion [24].
Mitochondrial function and reactive oxygen pathways are
already targets in the study of neurodegeneration [25-28].
In this study we determined the transcription profile of
Hsa21 genes in the heart of human fetuses at 18–22 weeks
of gestation. Our goal was to understand how upregula-
tion of Hsa21 genes may influence the expression of genes
mapping on other chromosomes and potentially involved
in CHD. We investigated the differential gene expression
and pathway dysregulation associated with Hsa21 tri-
somy in fetal hearts using DNA microarray technology
and functional analysis. By comparing heart samples from
fetuses with or without Hsa21 trisomy, we observed the
upregulation of most, but not all, Hsa21 genes as well as
the differential expression of genes located on different
chromosomes. We found that downregulation of several
mitochondrial genes and upregulation of many extracel-




Cardiac tissue was obtained from fetuses at 18–22 weeks
of gestation after therapeutic abortion. Ten samples from
fetuses trisomic for Hsa21 and 5 from euploid, control
fetuses were studied. At autopsy, the phenotype of the
fetuses with Hsa21 trisomy was found to be consistent
with DS. The presence of CHD was established by direct
examination at the time of tissue explantation and was
confirmed by histological analysis of a portion of the
heart (see Materials and Methods). The demographic data
of the analyzed samples are shown in Table 1.
Analysis of the fetal heart transcriptome
The gene expression profile of the 15 fetal hearts was
determined by DNA microarray analysis using Affymetrix
HG-U133A oligonucleotide arrays. The 22,283 probe sets
represented on the Affymetrix chip corresponded to
~14,500 genes and 500 expressed sequence tags and
clones. Affymetrix Microarray Suite (MAS 5.0) software
was used to identify presence calls and to quantify gene
expression. We first determined the total number of genes
expressed in the fetal hearts by assessing the number of
presence calls. Approximately 7,200 probe sets, corre-
sponding to ~5,100 individual genes, were called present
in all the analyzed samples. We also calculated how many
genes were called present in at least 2/3 of the samples,
and found that ~10,400 probe sets, corresponding to
~7,500 individual genes, were called present in at least 10
samples. This might represent a more reliable estimate of
expressed genes since the MAS 5.0 software underesti-Page 2 of 15
(page number not for citation purposes)
BMC Genomics 2007, 8:268 http://www.biomedcentral.com/1471-2164/8/268mates presence calls [29]. Expressed genes and their pres-
ence calls are reported (see Additional file 1).
Expression of Hsa21 genes
The Affymetrix HG-U133A chip includes 262 probe sets
that correspond to 168 known genes mapping on Hsa21.
Eighty-one probe sets, corresponding to 63 individual
genes, were called present in all analyzed samples. If we
consider genes called present in at least 10 out of 15 sam-
ples, 117 probe sets, corresponding to 87 Hsa21 genes,
might be regarded as being expressed in the human heart
at 18–22 weeks of gestation (see Additional file 2). To
investigate whether Hsa21 genes were upregulated in the
heart tissue of DS fetuses, we compared the mean raw log-
transformed gene expression data from DS heart tissues
(DSH group) with the mean control sample values (NH
group). The DSH/NH ratio was 1.48 ± 0.35 for Hsa21
genes and ~1 for all chromosomes or for any other chro-
mosome (Figure 1). This difference was highly significant
(p < 0.0001; ANOVA test with Bonferroni post-hoc). Scat-
ter plot of DSH versus NH expression data shows that
more than 75% of Hsa21 genes had a DSH/NH ratio
above 1, whereas genes mapping on all other chromo-
somes were almost equally distributed above and below
the line corresponding to the ratio = 1 (see Additional file
3). The level of variation of expression of Hsa21 genes was
not very high, with a fold change ranging from 1.2 to 3.
Twenty-five genes had a fold change below 1.2 (see Addi-
tional file 2). Quantitative real-time PCR (qRT-PCR) anal-
yses performed on 14 Hsa21 genes, either upregulated or
not in DS samples, were in good agreement with the
microarray results (Table 2).
Analysis of differentially expressed genes
We compared the gene expression levels in DSH versus
NH fetuses. To this aim, raw expression data were normal-
ized and pre-filtered to eliminate unreliable data, thus
8,966 probe sets, corresponding to ~6,300 genes, were
considered for further analysis. Reliable gene expression
data with fold change DSH vs. NH > |1.2| and p < .05 were
filtered. A total of 473 genes were significantly either
downregulated (278 genes) or upregulated (195 genes) in
the DSH group versus the NH group (Figure 2). Thirty-two
of the upregulated genes were located on Hsa21 and
thereof 441 dysregulated genes were on different chromo-
somes (see Additional file 4).
Gene Ontology functional class scoring (GOTM software)
was performed by comparing the list of differentially
expressed genes to the complete set of genes spotted on
Table 1: Characteristics of the samples analyzed in the study
Telethon Bank ID Experiment ID Karyotype Age (gw) PMI (h) Heart defects GEO accession
NH GROUP
TB 26 H1 46,XY 20 3 NO GSM30867
TB 21 H2 46,XY 21 3 NO GSM30868
TB 30 H3 46,XY 20 1 NO GSM30869
TB 32 H4 46,XX 21 1 NO GSM30870
TB 23 H5 46,XX 21 4 NO GSM30871
DSH GROUP
TB 37 DH1 47,XY,+21 21 2 NO GSM30862
TB 43 DH3 47,XY,+21 20 3 NO GSM30863
TB 50 DH4 47,XY,+21 20 3 NO GSM30864
TB 47 DH5 47,XY,+21 19 4 NO GSM30865
TB 48 DH6 47,XY,+21 21 3 NO GSM30866
TB 9 CDH1 47,XY,+21 22 2 YES GSM30723
TB 33 CDH2 47,XY,+21 20 4 YES GSM30855
TB 55 CDH4 47,XX,+21 21 2 YES GSM30864
TB 22 CDH5 47,XX,+21 18 3 YES GSM30859
TB 57 CDH6 47,XX,+21 20 3 YES GSM30860
Experiment accession is GSE1789
DSH = Heart samples from fetuses with trisomy of Hsa21
NH = Heart samples from control fetuses
ID = identifier numbers
gw = gestational weeks
PMI(h) = Post-mortem interval (hours)
Heart defects: TB9, Fallot's trilogy; TB33, Ventricular Septal Defect; TB55 Atrio-Ventricular Canal Defect; TB22 and TB57, Fallot's Tetralogy.
GEO = Gene Expression OmnibusPage 3 of 15
(page number not for citation purposes)
BMC Genomics 2007, 8:268 http://www.biomedcentral.com/1471-2164/8/268the Affymetrix HG-U133A chip, chosen as reference list.
Forty-four enriched categories for downregulated genes
(Table 3) and 19 enriched categories for upregulated
genes (Table 4) were identified. The ratios between
observed and expected genes for the most represented GO
categories and their p-values are reported (Tables 3 and
4). The most enriched GO cellular component categories
were mitochondrial-related, for downregulated genes,
and extracellular matrix (ECM)-related, for upregulated
genes. At least 65 genes encoding mitochondrial enzymes
were downregulated in the DS heart tissue out of the ~650
probe sets for mitochondrial proteins spotted on the HG-
U133A chip (530 detected in heart tissue), and 40 genes
out of the ~700 probe sets encoding ECM proteins (340
detected in the heart tissue), were upregulated in DSH
samples (see Additional file 5).
Pathway analysis with Pathway Miner software revealed
that 'oxidative phosphorylation' (OXPHOS) was the path-
way most influenced by Hsa21 trisomy, because at least
16 genes out of the 119 represented on the chip, were
downregulated in Hsa21 trisomy and no upregulated oxi-
dative phosphorylation genes were detected (Figure 3).
The second most affected pathway was 'focal adhesion',
which contained upregulated genes that mostly encode
ECM proteins (Figure 3).
To verify that these results were not affected by the meth-
ods of data processing and data analysis, a list of differen-
tially expressed genes was generated after a different pre-
processing method (gcRMA) and the functional analysis
was performed with a different software tool, the Gene Set
Enrichment Analysis (GSEA) [30]. A total of 532 genes
(49 located on Hsa21), with a fold change higher than
|1.2| and p < .05, were found to be differentially expressed
in the comparison between DSH and NH samples (see
Additional file 6). Using the GSEA to identify gene sets
that correlated with the DS condition, we obtained five
biologically informative gene sets (see Additional file 7).
These included two sets of genes whose upregulation was
highly correlated with DS (ECM and Cell Adhesion), and
three sets of genes whose downregulation was highly cor-
related with DS (Mitochondria, Electron Transport Chain
and OXPHOS). These results are in very good agreement
with functional analysis carried out with MAS 5.0 pre-
processed data and the GOTM and Pathway Miner web
tools.
Unsupervised classification of samples based on the simi-
larity of expression data across a gene list of ~900 genes,
not mapping to Hsa21 and encoding mitochondrial and
ECM proteins, yielded a condition tree in which trisomic
samples are perfectly separated from control samples (see
Additional file 8).
The results of microarray analysis were confirmed by qRT-
PCR for 9 OXPHOS genes and for 7 ECM genes (Table 2).
Expression of DYRK1A, DSCR1 and NFATc genes
The calcineurin/NFAT signaling pathway is known to be a
critical regulator of organogenesis [31] and the NFATc
transcription factors are transiently expressed in the endo-
cardial cushions during heart septation [32]. The DSCR1
and DYRK1A genes, both mapping on Hsa21 within the
critical region for DS, act synergistically to prevent nuclear
translocation of NFATc transcription factors and may
cause their downregulation [33]. We therefore examined
the expression of DYRK1A and DSCR1 and of genes of the
calcineurin pathway (NFATc1–4) in DSH and NH sam-
ples. DYRK1A was upregulated and NFATc2 downregu-
lated in the trisomic heart samples (Table 2, p < .05).
NFATc3 was also downregulated (p < .06). DSCR1 expres-
DSH/NH ratio of gene expression calculated for each chro-mosome and for all the chromosomesFigure 1
DSH/NH ratio of gene expression calculated for each 
chromosome and for all the chromosomes. Cumula-
tive gene expression (raw data) was calculated for each chro-
mosome and for all chromosomes and expressed as ratio 
between DSH and NH samples. Differences among chromo-
somes were evaluated using the ANOVA one-way test with 
Bonferroni post-hoc multiple comparison test. Only the dif-
ference between Hsa21 and any other chromosome is signif-
icant (p < 0.0001). Other comparisons among chromosomes 
are not statistically significant. The mean DSH/NHs ratio is 
~1 for all the chromosomes and 1.48 ± 0.35 for Hsa21. DSH 
= Heart samples from fetuses with Hsa21 trisomy (includes 
the samples: CDH1, CDH2, CDH4, CDH5, CDH6 from 
fetuses with heart defects, and the samples: DH1, DH3, 
DH4, DH5, DH6 from fetuses without heart defects). NH = 
Heart samples from control non trisomic fetuses (includes 
the samples: H1, H2, H3, H4, H5).Page 4 of 15






























































Table 2: Average expression ratios (DS samples/controls) calculated from microarray and RT-PCR data and Pearson correlation coefficient (r) between microarray and RT-PCR 
data. Hsa21 genes are in bold.
Functional Category Probe ID Gene Name GenBank Micro-array Fold change Micro-array p-value RT-PCR ratio r Primers for RT-PCR
Oxydative Phospho-rylation 201226_at NDUFB8 NM_005004 0.65 0.0160 0.76 0.78 LEFT-GCCAAGAAGTATAATATGCGTGTG
RIGHT-GTCAGGGAGCTTCGGGTAG
201740_at NDUFS3 NM_004551 0.76 0.0294 0.60 0.88 LEFT-GATTATGGCTTCGAGGGACA
RIGHT-ACCCGCTTCACTTCATCATC
201903_at UQCRC1 NM_003365 0.77 0.0142 0.89 0.84 LEFT-CCGAGCAGTCCTCTCAGC
RIGHT-TGTTCCCTTGAAAGCCAGAT
201966_at NDUFS2 NM_004550 0.67 0.0010 0.58 0.89 LEFT-GAATGGGCACAGCAGTTTG
RIGHT-GGCCCAAAGTTCAGGGTAAT
203606_at NDUFS6 NM_004553 0.75 0.0464 0.63 0.84 LEFT-AGAAGGTCACGCACACTGG
RIGHT-CACGGGCTGCTCTGCTAT
203663_s_at COX5A NM_004255 0.79 0.0400 1.04 0.79 LEFT-AACTGGGCCTTGACAAAGTG
RIGHT-GGTAACTGTTCACACTCAAGTAGCA
203858_s_at COX10 NM_001303 0.77 0.0101 0.66 0.92 LEFT-CTTTTGACTGGCCCTGTTTC
RIGHT-ACCAGCGGTCTGTTCTTTGT
218160_at NDUFA8 NM_014222 0.73 0.0445 0.71 0.94 LEFT-GTCATGCCGGGGATAGTG
RIGHT-TTAAGCACAGCAGAACTAATTTTCA
218190_s_at UCRC NM_013387 0.76 0.0017 0.76 0.89 LEFT-GACGCTATCTACGACCACATCA
RIGHT-GGTCCTTCTGGCCTGGAT
Extra-cellular Matrix 201069_at MMP2 NM_004530 1.59 0.0069 1.89 0.93 LEFT-TCCACCACCTACAACTTTGAGA
RIGHT-AACTTGCAGGGCTGTCCTT
202310_s_at COL1A1 K01228 1.55 0.0333 5.86 0.90 LEFT-TGTTCAGCTTTGTGGACCTC
RIGHT-CTGTACGCAGGTGATTGGTG
202403_s_at COL1A2 NM_000089 1.60 0.0192 3.59 0.77 LEFT-CACATGCCGTGACTTGAGAC
RIGHT-TAGCATCCATAGTGCATCCTTG
202994_s_at FBLN1 Z95331 1.72 0.0271 2.38 0.89 LEFT-GCCACAAGTGCGAGAACAC
RIGHT-TAGACGTTGGCACACTCCTG
209081_s_at COL18A1 AF018081 1.57 0.0079 1.91 0.95 LEFT-GTGGCCCTCTACGTGGACT
RIGHT-TCTGAGTCATCGCCTTCCTC
213428_s_at COL6A1 AA292373 1.62 0.0493 2.20 0.78 LEFT-AGGAGACCCTGGTGAAGCTG
RIGHT-AGGTCCTGGGGCTCCTCT
209156_s_at COL6A2 AY029208 2.39 0.0002 2.18 0.79 LEFT-GACCTGGTCGCTGAGAAGTT
RIGHT-GCCTTGTGGAAGTTCTGCTC
Other genes 205548_s_at BTG3 NM006806 1.68 0.0134 1.62 0.83 LEFT-GAGGCAGTTGAGAGGTTTGC
RIGHT-GAGTGAGCTCCTTTGGCAAG
35776_at ITSN1 AF064243 1.72 0.0003 1.57 0.88 LEFT-GTGAGCGGCACTGATTTGT
RIGHT-GATCATGCTTCGCTCTTTCC
205593_s_at PDE9A NM_002606 2.05 0.0067 2.05 0.89 LEFT-CAGAACGCACTCCGTACAAA
RIGHT-TGGGCTCTACCTGTCCACTT
211065_x_at PFKL BC006422 1.42 0.0088 1.97 0.81 LEFT-GGTGGACCTGGAGAAGCTG
RIGHT-TCCAGGCGGAGTCAATGT
200642_at SOD1 NM_000454 1.16 >0.05 0.65 0.83 LEFT-GCATCATCAATTTCGAGCAG
RIGHT-CAGCCTCTGTATTATCTCCAA
203405_at DSCR2 NM_003720 1.15 >0.05 0.85 0.78 LEFT-AAAGACTCGGCGTGTTGTC
RIGHT-GAATTGCTGGGATTTTCCAT
202671_s_at PDXK NM_003681 1.12 >0.05 1.00 0.98 LEFT-CATACAGAGCCACGTCATCC
RIGHT-GCATAGCCTGTGTGGTTTGA
202325_s_at ATP5J NM_001685 1.00 >0.05 1.17 0.78 LEFT-TGTTTGGCTTCTGTCTCACC
RIGHT-GGCTGACCGAATGACAGAG
202749_at WRB NM_004627 1.17 >0.05 1.25 0.85 LEFT-CTCAGCTTCGTGTTTGGATG
RIGHT-ACTGTGGAGAGCTCCTGCTT
209033_s_at DYRK1A D86550 1.53 0.0001 1.71 0.84 LEFT-GATATCATATGGGTCAGGTCATTTT
RIGHT-CTGGACTGTAACATAACACAGTATGC
208370_s_at DSCR1 NM_004414 1.25 >0.05 4.35 0.83 LEFT-TTTGCTCAGACCTTACACATAGGA
RIGHT-GGGAGGGGAGATCAGAAACT
210555_s_at NFATC3 U85430 0.45 >0.05 0.54 0.97 LEFT-CTTTGCAATGGCAAGAGGA
RIGHT-GATGAGGCACAGGCAAAGAT
217526_at NFATC2 AI478300 0.77 0.019 0.67 0.84 LEFT-GAGTTCACATCCCAGAGTCCA
RIGHT-GAGCACTCGATGGGGTTAGA
BMC Genomics 2007, 8:268 http://www.biomedcentral.com/1471-2164/8/268sion in fetal hearts varied greatly among individual sam-
ples. It was not overall significantly up- or downregulated,
but its expression pattern was inversely correlated with
that of NFATc3, independently of trisomy or cardiopathy
(Figure 4). The Pearson correlation coefficient (r) was
equal to -0.66 (r2 = 0.44), p < 0.01.
Comparison between DS heart samples with and without 
CHD
The differential expression analysis of DS fetuses with
(CDH) and without (DH) cardiac defects revealed a
strong homogeneity between the 2 groups. Only 42 genes
were differentially expressed, 19 upregulated and 23
downregulated in the CDH group, with a fold change
ranging from |1.2| to |2|, p < .05 (Figure 5a). None of
these genes mapped on Hsa21. The same functional anal-
ysis that was used to compare trisomic and control sam-
ples did not produce any significant result when genes
differentially expressed in CDH vs. DH were considered.
Similarly, there were no differences in the expression of
mitochondrial and ECM genes between DS fetuses with
and without heart defects (Figure 5b–5c).
Discussion
Using DNA microarray analysis we have obtained infor-
mation about transcripts that are present in the human
fetal heart at 18–22 weeks of gestation. The data indicate
that approximately 50% of the 15,000 analyzed genes are
expressed in human fetal heart. The percentage of Hsa21
genes expressed in fetal hearts was not very different.
Upregulation of Hsa21 genes
We found that Hsa21 genes are upregulated in all trisomic
fetal hearts. This demonstrates that the concept of
increased transcription of Hsa21 genes in Hsa21 trisomy
applies to the human heart irrespective of CHD. The level
of upregulation is modest. If we consider the mean for all
Hsa21 genes analyzed, the fold increase in Hsa21 trisomy
hearts versus controls is close to 1.5. This result is highly
significant and confirms that microarrays can detect even
small differences in gene expression levels.
This modest gene upregulation is in agreement with data
obtained in developing human brain and heart [16,17], as
well as in the cerebellum [21,22] and in different tissues
[18-20] of adult Ts65Dn and Ts1Cje mice, two animal
models of Hsa21 trisomy. Despite the different experi-
mental conditions, an overall fold increase of ~1.5, which
is consistent with a 3:2 ratio between trisomic and euploid
fetuses, was reported in all these studies. However, the
global 1.5-fold increase does not simply result from a 1.5-
fold upregulation of each single gene. Indeed, whereas the
fold increase for most genes is between 1.4 and 1.8, 8
genes are upregulated more than 2-fold in the DSH group
and 25 genes are not upregulated in the DSH and NH
groups. These results, which have been confirmed by qRT-
PCR and are in agreement with another study [16], are
indicative of either compensatory effects or heterogeneity
in the regulatory mechanisms of Hsa21 genes. The gene
expression level of individual Hsa21 genes in the heart of
DS individuals is of central relevance in the effort to
understand how Hsa21 trisomy causes CHD. Upregula-
tion of a single gene or a combination of dysregulated
genes might be at the base of CHD. Measurement of the
levels of proteins corresponding to upregulated genes may
shed light on the link between Hsa21 trisomy and CHD;
a limited amount of information is available on this issue
[34-36].
Downregulation of mitochondrial genes
Our finding that 441 extra-Hsa21 genes were dysregulated
in all trisomic samples supports the hypothesis that genes
outside of Hsa21 might play a role in determining DS fea-
tures [37]. Functional analysis of the genes differentially
expressed between trisomic and control samples shows
global downregulation of genes encoding mitochondrial
proteins, especially enzymes involved in the oxidative
phosphorylation pathway. Genes from all five complexes
were downregulated suggesting that the corresponding
proteins and enzymatic activities might be reduced, and
that the mitochondrial function could be consequently
impaired.
Volcano plot of genes differentially expressed between tri-somic and control samplesFigure 2
Volcano plot of genes differentially expressed 
between trisomic and control samples. The log2 of fold 
change between trisomic and control samples is represented 
on the x-axis and the negative log of p-values from the t-test 
is represented on the y-axis. Genes upregulated in the tri-
somic samples are on the right of the horizontal axis 0 value; 
genes downregulated are on the left. Red dots indicate 473 
genes that are significantly up- or down-regulated in the tri-
somic samples compared to the control samples (p < 0.05). 
Yellow dots indicate genes with no significant variation.Page 6 of 15
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Table 3: Enriched GO categories for down-regulated genes, sorted by p-value of the comparison between observed and expected data
GO Category Observed Expected Ratio p-value
Biological Process
gener. of precursor metabolites and energy 30 9.78 3.07 3.31E-08
oxidative phosphorylation 9 1.28 7.03 4.43E-06
ATP synth. Coupled electron transp. 6 0.49 12.24 6.55E-06
coenzyme metabolism 12 2.65 4.53 1.26E-05
mitochondrial electron transport 5 0.41 12.2 3.84E-05
acetyl-CoA metabolism 5 0.56 8.93 0.000193
electron transport 15 5.51 2.72 0.000408
main pathways of carbohydrate metabolism 8 1.92 4.17 0.00065
glucose catabolism 6 1.15 5.22 0.000966
monosaccharide catabolism 6 1.32 4.55 0.001998
hexose catabolism 6 1.32 4.55 0.001998
energy derivation by oxid. of organic comp. 9 2.84 3.17 0.00214
alcohol catabolism 6 1.35 4.44 0.00217
Glycolysis 5 0.94 5.32 0.002329
porphyrin biosynthesis 3 0.28 10.71 0.002341
porphyrin metabolism 3 0.34 8.82 0.004372
group transfer coenzyme metabolism 5 1.11 4.5 0.004859
cellular carbohydrate catabolism 6 1.73 3.47 0.00756
carbohydrate catabolism 6 1.73 3.47 0.00756
glucose metabolism 6 1.77 3.39 0.008491
Molecular Function
electron carrier activity 9 1.14 7.89 1.7E-06
NADH dehydrogenase activity 7 0.69 10.14 4.11E-06
hydrogen ion transporter activity 12 2.39 5.02 4.48E-06
oxidoreductase activity, acting on NADH/NADPH 8 1.02 7.84 6.63E-06
sodium ion transporter activity 7 0.75 9.33 7.61E-06
primary active transporter activity 13 3 4.33 8.97E-06
monovalent inorganic cation transporter activity 12 2.58 4.65 9.83E-06
metal ion transporter activity 9 1.56 5.77 2.34E-05
oxidoreductase activity 23 10.05 2.29 0.000172
electron transporter activity 12 4.37 2.75 0.001446
carrier activity 16 6.91 2.32 0.001523
metal cluster binding 4 0.52 7.69 0.001633
iron-sulfur cluster binding 4 0.52 7.69 0.001633
unfolded protein binding 8 2.62 3.05 0.004727
Cellular component
mitochondrion 48 10.2 4.71 3E-20
mitochondrial envelope 10 2.45 4.08 0.000163
mitochondrial inner membrane 8 1.61 4.97 0.000194
mitochondrial membrane 9 2.07 4.35 0.000217
organelle envelope 13 4.21 3.09 0.000296
envelope 13 4.25 3.06 0.000326
organelle inner membrane 8 1.8 4.44 0.000417
membrane-enclosed lumen 19 8.37 2.27 0.000692
organelle lumen 19 8.37 2.27 0.000692
nucleolus 6 1.82 3.3 0.009655
BMC Genomics 2007, 8:268 http://www.biomedcentral.com/1471-2164/8/268Protein levels of complex I, III and V were found to be
decreased in cerebellar and brain regions [38,39], and a
reduction of mitochondrial enzyme activity has been
reported in platelets from DS patients [40]. Moreover,
impaired mitochondrial function, indicated by reduced
mitochondrial redox activity and membrane potential,
has been observed in DS astrocytes and in primary cul-
tures of DS fibroblasts, [26,27]. More recently it has been
reported that the brain of the DS mouse model Ts1Cje has
decreased mitochondrial membrane potential and ATP
production [25]. These results are indicative of wide-
spread mitochondrial dysfunction in DS. Our data suggest
that mitochondrial dysfunction might also occur in DS
hearts and that the reduced expression of mitochondrial
genes might be the molecular basis of this dysfunction in
the heart as well as in other DS tissues. This is probably
not a primay effect of gene dosage because genes for mito-
chondrial function mapping on Hsa21 are either not
expressed or not differentially expressed in human fetal
hearts.
Upregulation of ECM genes
Functional analysis of the 473 differentially expressed
genes also demonstrates global upregulation of ECM pro-
tein genes. This group includes genes encoding adhesion
and ECM proteins that map on Hsa21 such as ADAMTS1,
ADAMTS5, APP, JAM2, COL6A1, COL6A2 and COL18A1,
which are dose-dependently upregulated in trisomic sam-
ples, and genes that do not map on Hsa21 such as
fibronectin, fibulin, collagen type I, type III, type V, type
XV, metalloproteases (MMPs) and several adhesion mole-
cule genes. Overexpression of this gene family is likely to
affect cell adhesion properties, possibly determining an
increase in adhesiveness. Cells explanted from endocar-
dial cushion derived structures of fetuses with Hsa21 tri-
somy are more adhesive in vitro than those from controls
[41]. A stochastic model has been proposed for septal
defects in DS by which higher values of adhesiveness
result in deficiencies of the atrio-ventricular canal devel-
opment associated with clinical variability among indi-
viduals based on chance alone [42,43].
Several of the ECM genes upregulated in trisomic samples
have been investigated for their potential role in DS cardi-
opathy. These include collagen type VI and MMPs. Colla-
gen type VI is expressed in the endocardial cushions
during septation, persists during valve differentiation and
is implicated in endocardial cushion differentiation. Its
pronounced expression in Hsa21 trisomy might lead to
AVSD [44]. MMPs are involved in cardiac organogenesis
by regulating cell proliferation, epithelial to mesenchymal
transition, ECM remodeling and degradation. MMP2, in
particular, coordinates prelooping stages, heart tube for-
mation and selective ECM degradation. It has an impor-
Table 4: Enriched GO categories for upregulated genes, sorted by p-value
GO categories Observed Expected Ratio p-value
Biological process
phosphate transport 8 0.98 8.16 5.27E-06
cell adhesion 22 8.15 2.7 1.81E-05
anion transport 9 2.15 4.19 0.000297
inorganic anion transport 8 1.77 4.52 0.000378
axonogenesis 5 0.66 7.58 0.000471
neuron morphogen. during different. 5 0.74 6.76 0.000807
neurite morphogenesis 5 0.74 6.76 0.000807
neuron development 5 0.98 5.1 0.002889
cell development 6 1.45 4.14 0.003197
neuron differentiation 5 1.14 4.39 0.005565
neurogenesis 5 1.19 4.2 0.006627
Molecular Function
extracellular matrix struct. const. 10 1.25 8 4.11E-07
integrin binding 4 0.43 9.3 0.000833
copper ion binding 5 0.82 6.1 0.00128
Cellular Component
extracellular matrix 22 3.55 6.2 5E-12
collagen 8 0.5 16 2.08E-08
extracellular region 35 14.17 2.47 2.83E-07
fibrillar collagen 4 0.16 25 1.24E-05
actin cytoskeleton 8 2.78 2.88 0.006602Page 8 of 15
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BMC Genomics 2007, 8:268 http://www.biomedcentral.com/1471-2164/8/268tant functional role in early cardiogenesis, neural crest cell
and cardiac cushion migration and remodeling of the
pharyngeal arches and cardiac heart tube [45,46].
It is interesting that DNA microarray analysis from right
ventricular biopsies of patients with tetralogy of Fallot
demonstrated that genes encoding ECM proteins, such as
collagen type I, III, IX, XV and fibronectin, were upregu-
lated versus age-matched controls [47], suggesting that the
increase of these ECM proteins has a potential role in
CHD.
Genes and gene pathways affected by Hsa21 trisomyFigure 3
Genes and gene pathways affected by Hsa21 trisomy. Pathway analysis was performed with Pathway Miner software on 
the 473 genes dysregulated in trisomic samples. The most affected pathways are: Oxidative Phosphorylation (cluster 1), con-
taining 16 genes downregulated in trisomic samples, and Focal Adhesion (cluster 2), containing at least 7 genes upregulated in 
trisomic samples. Cluster 3 is a network of Cell Adhesion genes, mostly upregulated in trisomic samples. Downregulated genes 
in cluster 1 are all mitochondrial genes; upregulated genes in clusters 2 and 3 are mostly ECM genes. Green indicates downreg-
ulated genes (darker green = more downregulated); red indicates upregulated genes (darker red = more upregulated).Page 9 of 15
(page number not for citation purposes)
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of other genes?
A key issue of DS pathogenesis is to understand how
upregulation of Hsa21 genes might dysregulate genes on
different chromosomes. Recently, a link has been pro-
posed between two Hsa21 genes, DYRK1A and DSCR1,
and the NFATc family of genes. NFATc-null mice show
phenotypic anomalies that resemble those observed in
human DS and 65% of NFATc1–4-null mice have endo-
cardial cushion defects [33]. Even modest overexpression
of DYRK1A decreases NFATc protein activity and levels
and may induce vascular and cardiac defects [33]. DSCR1
also encodes a regulatory protein that is expressed in heart
tissue [48] and exerts an inhibitory effect on the cal-
cineurin/NFAT signaling pathway [49], although different
protein isoforms may have opposite effects [50]. To verify
whether these genes affect the heart of DS fetuses, we eval-
uated their differential expression both by microarray and
by qRT-PCR. Our analyses show that DYRK1A is upregu-
lated and that NFATc2 and NFATc3 are downregulated in
Hsa21 trisomic samples. Moreover, an increase in DSCR1
expression in individual hearts correlated with a decrease
in NFATc3 expression. Recent data show that the enzy-
matic activity of complex II and IV of the respiratory chain
and mitochondrial oxidative activity are reduced in
Nfatc3-/-; Nfatc4-/- cardiomyocytes [51] suggesting that
the calcineurin/NFAT pathway affects mitochondrial
activity during heart development. We propose that
upregulation of DIRK1A and/or DSCR1 in DS might affect
mitochondrial gene expression, and thereafter mitochon-
drial function, through the calcineurin/NFAT pathway.
Mitochondrial abnormalities and a decrease of COX activ-
ity might also be induced by overproduction of beta APP
[52], a gene mapping on Hsa21, although the TS1Cje
mouse model, in which APP is not triplicated, also shows
Volcano plots obtained by comparing DS fetuses with and without cardiac defectsFigure 5
Volcano plots obtained by comparing DS fetuses with 
and without cardiac defects. Forty-two of the 15,000 
analyzed genes are differentially expressed in the 5 samples 
with cardiac anomalies (CDH) and the 5 samples without 
cardiac anomalies (DH) (6a). Only a few genes of the ~600 
encoding mitochondrial proteins (6b) and of the ~700 encod-
ing ECM proteins (6c), are dysregulated in the CDH vs. DH 
comparison. Red dots indicate genes differentially expressed 
with fold change >1.2 and p < .05; yellow dots indicate genes 
with no significant variation.
Expression level of DSCR1 and NFATC3 genes in individual hea t amplesFigure 4
Expression level of DSCR1 and NFATC3 genes in 
individual heart samples. Microarray expression values of 
DSCR1 (red line) and NFATC3 (green line) genes of individ-
ual trisomic hearts (CDH1, CDH2, CDH4, CDH5, CDH6 
and DH1, DH3, DH4, DH5, DH6) and individual normal 
hearts (H1, H2, H3, H4, H5) show an inverse correlation (r = 
-066) between the two genes.Page 10 of 15
(page number not for citation purposes)
BMC Genomics 2007, 8:268 http://www.biomedcentral.com/1471-2164/8/268decreased mitochondrial function and ATP production
[25]. The transcription factor GABPalpha, which is
encoded by a gene on Hsa21, is another regulator of the
expression of genes involved in mitochondrial respiration
[28]. However, GABPalpha was not expressed in fetal
hearts at 18–22 weeks of gestation, although it cannot be
excluded that it is expressed at different embryonic or fetal
stages.
Type VI collagen gene upregulation also sheds light on the
potential interplay between Hsa21 genes and genes on
different chromosomes. Type VI collagen, together with
other collagens, is an activator of discoidin domain recep-
tor tyrosine kinases (DDRs) [53,54]. Activated DDRs, in
turn, induce the expression of metalloproteases such as
MMP1 and MMP2 [53] and of other ECM proteins [55].
Moreover, DDR1 and DDR2 are upregulated in trisomic
heart samples (see Additional file 4) and DDR2 expres-
sion has been detected by confocal microscopy in devel-
oping heart, within the cardiac cushions and eventually
within the septum [56].
Conclusion
The expression of most Hsa21 genes and of many genes
located on other chromosomes were dysregulated in the
heart of trisomic fetuses at 18–22 weeks of gestation.
Genes encoding mitochondrial enzymes were signifi-
cantly downregulated, whereas genes encoding ECM pro-
teins were upregulated in all trisomic hearts, irrespective
of CHD. In fact, gene expression did not differ between
DS heart samples with or without cardiopathy. This might
be due to some intrinsic limits of our approach (e.g., heart
developmental stage, and number of samples and genes
analyzed). We nevertheless demonstrate that the expres-
sion of several gene categories is dysregulated in the hearts
of all DS fetuses, and suggest that this dysregulated expres-
sion might be a prelude to heart defects. Other factors,
such as differences in the genetic background, different
Hsa21 haplotypes, stochastic and/or environmental fac-
tors, could play a critical role in determining the final
pathogenetic result. Finally, non-coding mRNAs as well as
conserved non-genic sequences, which have been
described within Hsa21, might be implicated in determin-
ing the DS phenotype [57].
Methods
Experimental design
Fifteen human fetuses from 18- to 22-week-gestation with
and without Hsa21 trisomy were analyzed. Ten were tri-
somic for Hsa21; 5 non trisomic fetuses served as controls.
Diagnosis, gestational age, gender and karyotype are pro-
vided in Table 1. Control samples were euploid fetuses
without cardiac anomalies. Fetuses H1 and H5 were
aborted because of the mother's condition; they did not
show any disorder at autopsy examination. Two other
fetuses were affected by genetic anomalies: fragile X syn-
drome (H2) and thalassemia (H4). Fetus H3 was affected
by severe hydropia. The experimental design was diseased
versus control comparison. The conditions tested were
gene expression at 18–22 weeks of gestation and genetic
variation.
Samples
Heart tissue was used for total RNA extraction. All cardiac
samples were obtained from the Telethon Bank of Fetal
Biological Samples at the University of Naples. We used
protocols approved by our Institutional Ethics Commit-
tee. The hearts were explanted from fetuses after therapeu-
tic abortion. The posterior half, representative of all four
chambers, was dissected by a longitudinal cut and imme-
diately frozen in liquid nitrogen and stored at -135°C for
RNA extraction. The anterior half was paraffin-embedded.
Fetal karyotype was determined on amniocytes, and was
confirmed on cultured fibroblasts, by standard cytoge-
netic methods with G banding.
Microarray hybridization procedure
All experiments were performed with Affymetrix HG-
U133A oligonucleotide arrays (Affymetrix, Santa Clara,
CA), as described at [58]. Total RNA from each sample
was extracted using TRIzol reagent (Gibco/BRL Life Tech-
nologies, Inc., Gaithersburg, MD) and used to prepare
biotinylated target cRNA, according to the Affymetrix rec-
ommendations [58]. Purification of PolyA+ mRNA from
total RNA was performed with the Oligotex mRNA Kit
(QIAGEN GmbH, Hilden, Germany): 1 μg of mRNA was
used to generate first-strand cDNA by using a T7-linked
oligo(dT) primer; after second-strand synthesis, in-vitro
transcription was performed with biotinylated UTP and
CTP using the Enzo BioArray High Yield RNA Transcript
Labeling Kit (Enzo Diagnostics, Farmingdale, NY), result-
ing in approximately 100-fold amplification of RNA. The
target cRNA generated from each sample was processed as
recommended by the manufacturer and using an Affyme-
trix GeneChip Instrument System. Fragmentation of bioti-
nylated cRNA, washing and staining were done according
to the instructions provided by Affymetrix. Briefly, spike
controls were added to 10 μg fragmented cRNA before
overnight hybridization. Arrays were then washed and
stained with streptavidin-phycoerythrin, before being
scanned on an Affymetrix GeneChip scanner. Quality and
amount of starting RNA was confirmed using spectropho-
tometry and agarose gel electrophoresis. A detailed
description of these procedures is available [58].
Data acquisition and processing
After scanning, array images were assessed by eye to con-
firm scanner alignment and the absence of significant
bubbles or scratches on the chip surface. 3'/5' ratios for
GAPDH and beta-actin were confirmed to be withinPage 11 of 15
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were found to be present on all chips, with BioC, BioD
and CreX also present in increasing intensity. Expression
data were deposited in the Gene Expression Omnibus
repository [59] with experiment accession number
GSE1789.
Using the Affymetrix Software Microarray Suite (MAS
5.0), each probe set was assigned an "average difference"
value corresponding to the expression level of the particu-
lar gene it represented. To make comparisons across dif-
ferent chips, data sets on each chip were scaled to a
targeted total fluorescence of 100. When scaled to a target
intensity of 100 (using Affymetrix MAS 5.0 array analysis
software), scaling factors for all arrays were within accept-
able limits (0.69–1.51), as were background, Q values
and mean intensities. Affymetrix software also assigns
each probe set an absolute call (present, absent or mar-
ginal), which represents a qualitative indication of
whether or not a transcript is detected within a sample.
Array scanning data (CEL files) were also pre-processed
using the gcRMA algorithm [60]. Raw data were prefil-
tered to exclude fluorescence intensities lower than 10,
which are indistinguishable from background. Unreliable
genes were also discarded using the cross gene error model
[61]. This analysis showed an overall 90% agreement with
the MAS 5.0 data analysis; 40% of this agreement was for
fold change only, but the p-value was higher.
GeneSpring software (Silicon Genetics, Redwood City,
CA) was used for data mining. Raw expression data were
normalized per gene by dividing each measurement for
each gene by the median of that gene's measurements in
the corresponding control non trisomic samples. Normal-
ized data were log-transformed. Based on Affymetrix
absolute call, we determined the total number of genes
that were expressed (i.e. called present) in human fetal
heart.
Although the Affymetrix chip HG-U133A can measure the
expression of ~15,000 genes, the true transcript level is
often affected by a substantial amount of noise and varia-
bility induced by many sources including the manufactur-
ing processes and the experimental procedures [62]. We
pre-filtered expression data to reduce noise and so discard
"unreliable" genes. The Cross-Gene error model [61] was
applied to estimate measurement precision by combining
variability of gene expression data and assuming that
measurements with higher control strength are relatively
more precise than measurements with lower control
strength. After pre-filtering, genes were considered suita-
ble for differential evaluation if called present in at least 2
out of 15 samples and with a raw signal higher than 10.0.
Statistical evaluation of the differential analysis was per-
formed by one way ANOVA. The threshold for statistical
significance was set to 0.05.
Unsupervised classification of samples was performed
using the hierarchical clustering tool included in the
GeneSpring software. A condition tree was generated
grouping together DSH or NH samples based on the sim-
ilarity of their expression data in the specified list.
Bioinformatics data analyses
Gene ontology functional class scoring was performed
using the web-based GOTM software [63,64] which visu-
alizes genes from the list of differentially expressed genes
in the GO context, considering as gene sets all the GO cat-
egories for biological processes, molecular functions and
cellular components. The list of differentially expressed
genes was compared to the complete list of genes spotted
on Affymetrix HG-U133 chip, in order to identify catego-
ries of genes more represented in the list of differentially
expressed genes than in the reference gene set.
Pathway analysis was performed by Pathway Miner soft-
ware [65,66] which catalogs genes of a list based on their
role in metabolic, cellular and regulatory pathways from
three different pathway databases (GenMap, Encarta and
KEGG). A Fisher exact test ranks pathways according to
the number of genes of the list which co-occurrs in path-
ways, considered as gene sets. Furthermore a network is
created among genes participating to multiple pathways.
Gene Set Enrichment Analysis (GSEA) was used as
described [30] to identify gene sets correlated with the DS
condition. The gcRMA output list of differentially
expressed genes was ranked per fold change and was sub-
mitted to the GSEA tool. Enrichment of functional gene
sets from the MSigDB C2 curated database [67] was tested.
This database includes sets of genes whose products are
involved in specific metabolic and signaling pathways
from public databases and sets of genes coregulated in
specific conditions. This last group of gene sets was not
considered in the analysis. In turn, the Gene Ontology cat-
egory of Extracellular Matrix genes (GO:31012, cellular
component) was added into the MSigDB C2 catalog.
Quantitative Real-Time PCR
We used the same sources of total RNA for both primary
gene expression and validation experiments. cDNA was
synthesized with random hexamer primers starting from
1.5 μg of total RNA using the reverse transcription proto-
col (Taqman Reverse Transcription, Applied Biosystems,
Applera, Monza, Italia). Real-time PCR was performed
using iQ Supermix SYBR Green 2X [68] on the Bio-Rad
iCycler [68] according to the manufacturer's protocols.
PCR reactions were performed in triplicate. The primers
(MWG Biotech, Ebersberg, Germany) used for amplifica-Page 12 of 15
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the Primer 3 software [69] to obtain amplicons ranging
from 100 to150 base pairs, and specifically designed to
span introns or cross intron-exon boundaries. In order to
test primer efficiency, serial dilutions of cDNAs generated
from selected human fetal hearts, that expressed target
genes at a suitable level, were used to generate standard
curves for each gene. RPL13A and GAPDH housekeeping
genes were chosen as reference genes.
List of abbreviations used
DS = Down syndrome
Hsa21 = Chromosome 21
CHD = Congenital heart defects
DSH = Heart samples from fetuses with Hsa21 trisomy
NH = Heart samples from non trisomic fetuses
DH = Samples without cardiac anomalies
CDH = Samples with cardiac anomalies
ECM = Extracellular matrix
OXPHOS = Oxidative phosphorylation
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Additional file 1
Genes expressed in human fetal heart at 18–22 weeks of gestation. Genes 
are reported if the Affymetrix presence call was 'Present' in at least 10 
heart samples. Genes are sorted by alphabetical order.




Hsa21 genes expressed in the human fetal heart at 18–22 weeks of gesta-
tion. Genes (probe sets) are sorted according to chromosomal location. 
Mitochondrial and ECM genes are in bold.




Scatter plot of gene expression data of trisomic samples vs. control samples. 
Mean raw, log transformed, gene expression data from the 5 control sam-
ples (NH) were plotted on the x-axis and data from the 10 trisomic sam-
ples (DSH) were plotted on the y-axis. Plots are shown for Hsa21 genes 
and for genes of all chromosomes excluding Hsa21. In the plot of Hsa21 
more than 75% of gene probe sets are above the line, whereas in the plot 
of all other chromosomes approximately the same number of gene probe 
sets is above and below the line. Abbreviations for DSH and NH are as in 
Figure 1.




Genes differentially expressed between trisomic and control samples. The 
table includes genes with fold change > |1.2| and p < 0.05 (ANOVA test). 
Genes are sorted according to fold change.




List of downregulated genes encoding mitochondrial proteins, and of 
upregulated genes encoding extracellular matrix proteins. Hsa21 genes 
are in bold.




Genes differentially expressed between trisomic and control samples using 
gc-RMA preprocessed data. The table includes genes with fold change > 
|1.2| and p < 0.05 (ANOVA test). Genes are sorted according to fold 
change. Hsa21 genes are in bold.




Enrichment score plots of the five biologically informative sets correlated 
to the DS condition with an FDR value < 0.05. Extracellular matrix and 
Cell adhesion gene sets are positively correlated to DS condition whereas 
Mitochondria, Electron transport chain and Oxidative phosphorylation 
gene sets are negatively correlated. The enrichment score (ES) represents 
the degree to which a gene set is enriched at the top (positive ES) or at the 
bottom (negative ES) of our ranked list. The size indicated for each gene 
set is the dimension of the leading edge subset that is the subset of mem-
bers of our list that contribute more to the enrichment score (ES). The 
nominal p-value and the False Discovery Rate (FDR) value estimate the 
probability that the enrichment score represents a false positive finding.
Click here for file
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